Leqembi, which was approved in 2023 to treat the mind-robbing disease, generated $168 million in sales, up 74 percent from ...

Alloy Therapeutics Inc. ("Alloy"), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug ...

When a biopharma company known for its expertise in a specific domain turns to a collaborator to expand its capabilities in that area, it serves as strong validation of the partner’s technology. It’s ...

Biogen plans to beef up its early-stage immunology pipeline by handing over $70 million in upfront cash for the rights to Vanqua Bio’s preclinical C5aR1 antagonist. Biogen described C5aR1 as a ...

A California judge has ruled that Biogen owes Roche $124 million in royalties for its use of intellectual property developed more than 40 years ago by the Swiss company’s subsidiary Genentech that ...

Join RAPS Boston for an in-person Executive Chat with Diane Rocco, SVP of Global Regulatory Affairs at Biogen, moderated by Ami Mehr. The discussion will explore how regulatory leadership shapes key ...

Eleanor Nkera during her final internship poster presentation at Biogen. From the Boston Business Journal. Eleanor Nkera grew up in Medford, Massachusetts, a stone’s throw away from the life sciences ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Charles Weissmann's ...

After attracting GSK with its subcutaneous delivery tech at the top of the year, South Korea’s Alteogen has snared another Big Pharma partner in Biogen. Biogen will hand Alteogen $20 million upfront ...

Biogen (NASDAQ:BIIB) is gearing up to announce its quarterly earnings on Thursday, 2025-10-30. Here's a quick overview of what investors should know before the release. Analysts are estimating that ...

Biogen Inc. forecast 2026 profit above Wall Street’s expectations, signaling that steep cost-cutting measures are cushioning the impact of shrinking sales from its multiple sclerosis franchise.

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Biogen said Tuesday that ...